Skip to content

Inflammatory Anemia Associated Parameters in Septic Patients

Mortality Associated Parameters With Inflammatory Anemia in Patients With Sepsis Admitted to the Intensive Care Unit and Blood Transfusion Effect

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04281888
Enrollment
100
Registered
2020-02-24
Start date
2020-03-20
Completion date
2021-05-20
Last updated
2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Response

Brief summary

1. To observe the changes in the inflammatory anemiaassociated parameters of patients with sepsis in the early stage of intensive care unit (ICU) admission. 2. To evaluate their association with 28-days mortality 3. To evaluate the effect of blood transfusion on these parameters and the survival of the studied patients

Detailed description

Anemia is one of the most common complications in patients with sepsis in the intensive care unit (ICU), as well as sepsis is a major cause of high mortality in ICU. Studies demonstrated that sepsis-related anemia can be caused by fluid loading related hemodilution, iatrogenic blood loss, decreases in iron supply, erythropoietin (EPO) production and erythrocyte lifespan . However, sepsis related anemia has been demonstrated to be associated mainly with inflammation (i.e., anemia of inflammation). Anemia of inflammation is usually a mild to moderately severe anemia (hemoglobin rarely \< 8 g/dL) . It develops in the setting of infection, inflammatory disease or malignancy, together with low serum iron despite adequate systemic iron stores, decreased serum transferrin, normal size of erythrocytes and hemoglobin content or mildly decreased size and hemoglobin content of erythrocytes if the inflammatory disease is longstanding . Impaired iron homeostasis and the suppressive effects of proinflammatory cytokines on erythropoiesis, together with alterations in the erythrocyte membrane that impair its survival may result, ultimately, in inflammation-associated anemia . Hepcidin is a key regulator of inflammation-associated anemia. Hepcidin reduces the iron level in plasma through: 1. direct inhibition of intestinal absorption of iron. 2. promotion of iron storage in macrophages by down regulating expression of ferroprotein in intestinal mucosae and macrophages. Increased interleukin-6 (IL-6) in patients with sepsis can induce an abruptly increased synthesis of hepcidin, causing decreased plasma iron. Plasma iron can be depressed by inflammation markedly (more than 50%) and rapidly ( with in 24 hrs). Also, the interaction between inflammation and iron metabolism may interfere with other inflammatory anemia associated parameters and complicate iron metabolism in patients with sepsis. Typically, plasma ferritin (which stores iron) is reduced in iron deficiency anemia but can increase in the acute phase of sepsis. Anemia usually results in an increased synthesis of EPO in kidneys in minutes to hours, but the response to EPO is blunted in patients with sepsis . The soluble transferrin receptor (sTfR), an early and sensitive biomarker for diagnosing iron deficiency , is particularly useful for identification of concomitant iron deficiency in patients with inflammation. The sTfR is not affected by inflammation, which is a significant advantage over other biomarkers. Plasma sTfR reflects the degree of iron availability for cells, whereas plasma ferritin reflects iron storage. Hence, the ratio of sTfR to log ferritin (hereafter termed sTfR/log ferritin) provides the efficacy of sTfR alone or ferritin alone in the diagnosis of iron deficiency. These cytokines have the propensity to promote iron restricted erythropoiesis, characterized by functional rather than absolute iron deficiency, occurring secondary to dysregulation of iron metabolism. Associations among inflammatory cytokines, EPO, and anemia in critically ill septic patients remain unclear. The inflammatory anemia-associated parameters mentioned above may change with the severity of inflammation in patients with sepsis. The sensitivity and specificity of these parameters can be modified if inflammation and iron deficiency are present concomitantly. This may complicate the diagnosis, evaluation, and treatment of inflammatory anemia. Hence, a better understanding of changes in the inflammatory anemia and associated parameters in patients with sepsis at the early stage of ICU admission is needed urgently. In addition, although severe anemia is associated with adverse outcomes in critical illness, a lowered plasma iron is part of the natural defense against pathogens. EPO has also been demonstrated to exert protective effects in the kidneys and lungs of mice with sepsis, but EPO deficiency contributes to anemia development in patients with sepsis. As a result of these effects, inflammatory anemia-associated parameters have been speculated to be associated with the prognosis of patients with sepsis , but relevant studies are lacking

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years

Inclusion criteria

1-patients meeting diagnostic criteria of sepsis and hemoglobin level less than 10 g/dl 2-patients admitted to the intensive care unit

Exclusion criteria

1. patients less than18 years of age. 2. patients have chronic liver dysfunctions or chronic kidney disease resulting from different causes. 3. patients with known iron related diseases (e.g., hemochromatosis), immunologic diseases or malignancies upon hospital admission; all types of anemia (aplastic, iron deficiency, hemolytic, megaloblastic). 4. patients with overt blood loss (e.g., gastrointestinal bleeding) upon admission and during the ICU stay.

Design outcomes

Primary

MeasureTime frameDescription
The relation between level of hepcidin, interleukin-6 and hemoglobin with 28-days mortality in 100 ICU septic patientsBaselineHepicidin level will be measured in day 1,3 and 7 of ICU admission as well as interleukin-6 and hemoglobin and the relation between their level and survival of the studied patients will be evaluated

Contacts

Primary ContactHeba M Ahmed, Hematologist
nfertiti.9981@yahoo.com00201061343995

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026